Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

Cannabis plants grow inside the Organigram facility in Moncton on Oct. 12, 2019.

John Morris/The Globe and Mail

Cannabis company Organigram Holdings Inc. is gearing up for the production of vape pens, cannabis infused chocolates and powdered beverages even as it faces uncertain demand for recreational marijuana.

The company said Monday it submitted new product notifications to Health Canada for a portfolio of vape pens and cannabis infused chocolates in October and expects to launch some vape pens next month and chocolates in the first three months of 2020.

Sales of powdered products to be added to a consumer’s beverage of choice are expected in the second quarter of 2020.

Story continues below advertisement

“This unique product allows us to enter the beverage space without having to secure bottling or canning equipment and incurring significant transport costs associated with liquid beverages,” CEO Greg Engel told analysts during a conference call.

The company based in Moncton, N.B., expects substantial construction of additional in-house extraction capacity and expanded vape pen filling space to be completed by the end of calendar 2019 at a cost of $60 million to $65 million.

It has also almost completed an automated chocolate production line which includes a chocolate moulding line and a fully integrated packaging line with advanced engineering, robotics, high-speed labelling and automated carton packing.

While Phase 5 expansion is continuing, the company has paused completion of its Moncton Phase 4 cultivation facility at 70 per cent for recreational marijuana until there’s more clarity on retail expansion in Canada, especially in Ontario.

“At this time, we believe this is adequate supply, adequate capacity to take advantage of the market opportunity in the short to medium term until market matures,” Engel said.

The company had warned earlier this month that revenue in its fourth-quarter would be lower than the third quarter.

However, Organigram said Monday it expects net revenue in the first-quarter of its 2020 financial year to rise compared with the fourth quarter of its 2019 financial year due to increased sales to provinces and higher wholesale revenue.

Story continues below advertisement

In reporting its full financial results, Organigram said its net loss from continuing operations totalled $22.5 million or 14 cents per diluted share for the quarter ended Aug. 31 compared with a profit of $18.1 million or 12 cents per share a year ago, due to non-cash fair value changes to biological assets and inventories.

Net revenue for its fourth quarter totalled $16.3 million, up from $3.2 million a year ago. However, the result was down from net revenue of $24.8 million in the third quarter.

It blamed slower than expected store openings in Ontario that was further exacerbated by increased industry supply. The company also said it faced a high amount of product returns in the quarter related to two products sold to the Ontario Cannabis Store.

For the full-year, the company lost $9.5 million on $80.4 million of net revenue, compared with a $22.1 million profit on $12.4 million of revenues in 2018. The results included a gain of $10.6 million in fair value changes to biological assets and inventories, compared with a gain of $46 million a year ago.

Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies